HK1251547A1 - 嘧啶或吡啶並吡啶酮類化合物及其應用 - Google Patents

嘧啶或吡啶並吡啶酮類化合物及其應用

Info

Publication number
HK1251547A1
HK1251547A1 HK18110804.5A HK18110804A HK1251547A1 HK 1251547 A1 HK1251547 A1 HK 1251547A1 HK 18110804 A HK18110804 A HK 18110804A HK 1251547 A1 HK1251547 A1 HK 1251547A1
Authority
HK
Hong Kong
Prior art keywords
pyrimidine
application
pyridopyridone compound
pyridopyridone
compound
Prior art date
Application number
HK18110804.5A
Other languages
English (en)
Inventor
蔡雄
錢長庚
李軍旗
卿遠輝
王豔豔
薛偉才
游華金
Original Assignee
廣州必貝特醫藥技術有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 廣州必貝特醫藥技術有限公司 filed Critical 廣州必貝特醫藥技術有限公司
Publication of HK1251547A1 publication Critical patent/HK1251547A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK18110804.5A 2015-09-30 2018-08-22 嘧啶或吡啶並吡啶酮類化合物及其應用 HK1251547A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510646418.4A CN105130986B (zh) 2015-09-30 2015-09-30 嘧啶或吡啶并吡啶酮类化合物及其应用
PCT/CN2016/084056 WO2017054484A1 (zh) 2015-09-30 2016-05-31 嘧啶或吡啶并吡啶酮类化合物及其应用

Publications (1)

Publication Number Publication Date
HK1251547A1 true HK1251547A1 (zh) 2019-02-01

Family

ID=54716613

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110804.5A HK1251547A1 (zh) 2015-09-30 2018-08-22 嘧啶或吡啶並吡啶酮類化合物及其應用

Country Status (15)

Country Link
US (1) US10183941B2 (zh)
EP (1) EP3357922B1 (zh)
JP (1) JP6556369B2 (zh)
CN (1) CN105130986B (zh)
AU (1) AU2016333188B2 (zh)
CA (1) CA3000548C (zh)
DK (1) DK3357922T3 (zh)
ES (1) ES2828984T3 (zh)
HK (1) HK1251547A1 (zh)
HR (1) HRP20201727T1 (zh)
HU (1) HUE052454T2 (zh)
PL (1) PL3357922T3 (zh)
PT (1) PT3357922T (zh)
SI (1) SI3357922T1 (zh)
WO (1) WO2017054484A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016169422A1 (zh) * 2015-04-22 2016-10-27 江苏恒瑞医药股份有限公司 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法
US11225492B2 (en) * 2015-12-13 2022-01-18 Hangzhou Innogate Pharma Co., Ltd. Heterocycles useful as anti-cancer agents
CN106083844B (zh) * 2016-06-05 2017-11-10 陈志明 一种制备抗乳腺癌药物帕博西尼中间体的方法
RU2747311C2 (ru) * 2016-12-16 2021-05-04 СиСТОУН ФАРМАСЬЮТИКАЛС (СУЧЖОУ) КО., ЛТД. Ингибитор CDK4/6
WO2019015593A1 (zh) * 2017-07-19 2019-01-24 江苏奥赛康药业股份有限公司 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用
CN112292379B (zh) * 2018-06-13 2022-03-04 基石药业(苏州)有限公司 吡啶并吡啶酮衍生物的盐型及晶型
CN109320511A (zh) * 2018-10-26 2019-02-12 广安凯特制药有限公司 一种高纯度帕博西尼中间体产品及其制备方法
WO2021108803A1 (en) 2019-11-26 2021-06-03 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as jak inhibitors
US20230135215A1 (en) * 2020-02-28 2023-05-04 Fochon Biosciences, Ltd. Compounds as cdk2/4/6 inhibitors
AR124154A1 (es) 2020-11-27 2023-02-22 Rhizen Pharmaceuticals Ag Inhibidores de cdk
CN112457311B (zh) * 2020-12-04 2022-07-12 江苏豪森药业集团有限公司 一种含有氯溴吡咯嘧啶酮结构化合物的制备方法
CN112778303A (zh) * 2020-12-31 2021-05-11 武汉九州钰民医药科技有限公司 Cdk4/6激酶抑制剂shr6390的制备方法
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
CN114751909B (zh) * 2022-03-17 2023-10-27 杭州福斯特药业有限公司 一种瑞博西尼中间体的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20063909B (en) * 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
ATE439361T1 (de) * 2006-01-31 2009-08-15 Hoffmann La Roche 7h-pyridoä3,4-düpyrimidin-8-one, ihre herstellung und ihre verwendung als proteinkinaseinhibitoren
PE20080695A1 (es) * 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
US20080114007A1 (en) * 2006-10-31 2008-05-15 Player Mark R 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
TW200942537A (en) * 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
CN103288824B (zh) * 2012-02-23 2015-12-09 上海师范大学 四氢吡啶并吡啶酮衍生物、其制备方法及应用
AU2013323736A1 (en) * 2012-09-26 2015-04-09 Mannkind Corporation Multiple kinase pathway inhibitors
CN104470921B (zh) * 2013-05-17 2017-05-03 上海恒瑞医药有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
US9828373B2 (en) * 2014-07-26 2017-11-28 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
WO2016169422A1 (zh) * 2015-04-22 2016-10-27 江苏恒瑞医药股份有限公司 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法

Also Published As

Publication number Publication date
EP3357922A4 (en) 2019-06-05
DK3357922T3 (da) 2020-11-02
HRP20201727T1 (hr) 2020-12-25
AU2016333188A1 (en) 2018-05-17
AU2016333188B2 (en) 2018-10-25
ES2828984T3 (es) 2021-05-28
US20180297995A1 (en) 2018-10-18
SI3357922T1 (sl) 2020-12-31
WO2017054484A1 (zh) 2017-04-06
PL3357922T3 (pl) 2021-02-08
JP2018534352A (ja) 2018-11-22
US10183941B2 (en) 2019-01-22
EP3357922A1 (en) 2018-08-08
CA3000548A1 (en) 2017-04-06
CN105130986A (zh) 2015-12-09
JP6556369B2 (ja) 2019-08-07
EP3357922B1 (en) 2020-08-26
HUE052454T2 (hu) 2021-04-28
CN105130986B (zh) 2017-07-18
PT3357922T (pt) 2020-10-29
CA3000548C (en) 2020-09-22

Similar Documents

Publication Publication Date Title
HK1255102A1 (zh) 雜環化合物及其應用
HK1255921A1 (zh) 嘧啶化合物
HK1251547A1 (zh) 嘧啶或吡啶並吡啶酮類化合物及其應用
IL273236A (en) Pyrazolopyrimidine compounds and their uses
IL259150B (en) Pyrimidine derivative and use thereof
SG11201706029VA (en) Anti-senescence compounds and uses thereof
HK1246780A1 (zh) 氮雜-吡啶酮化合物及其用途
ZA201705456B (en) Benzoxaborole compounds and uses thereof
IL292488B1 (en) Pyridineamine-pyridone and pyrimidineamine-pyridone compounds
GB201504763D0 (en) Compounds and uses
GB201616439D0 (en) Compounds and uses
IL254241A0 (en) Etv2 and its uses
GB201507753D0 (en) New compounds and uses
IL253459A0 (en) Isoergoline compounds and their uses
GB201718875D0 (en) Autophagy-inhibiting compounds and uses thereof
IL292482B1 (en) Azaindolylpyridone and diazaindolylpyridone compounds
GB201700404D0 (en) Compounds and composistions
GB201614224D0 (en) Compounds and uses thereof
IL258458B (en) Peroxyhemiacetal profragrant and proflavor compounds
GB2543375B (en) Compounds and their uses
GB201614874D0 (en) New compounds and uses
GB201602572D0 (en) New compound and uses
GB201507752D0 (en) New compounds and uses